PD-L1 expression is regulated by NF-κB via inflammatory signaling such as IL1R, TLR, and IFN signals49, which were linked to the imatinib-insensitivity of CML LSCs in our RNASeq analysis. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.